Strong Growth Ahead: Benign Prostatic Hyperplasia Treatment Market Size To Grow At Arecord 5.6% Cagr By 2029

We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.

How Big Is the Benign Prostatic Hyperplasia Treatment Market Size Expected to Be by 2034?
The market for treating benign prostatic hyperplasia has witnessed robust growth over the past few years. It is anticipated to expand from $8.23 billion in 2024 to $8.71 billion in 2025, with a compound annual growth rate (CAGR) of 5.9%. The expansion during the historic period can be attributed to elevated awareness and initiation of screening programs, a surge in the number of BPH cases, heightened consciousness about health care, advancements in the healthcare infrastructure, and an increasing elderly population.

The market size for benign prostatic hyperplasia treatment is predicted to experience significant expansion in the coming years, potentially reaching a value of $10.83 billion by 2029. This predicted growth, at a compound annual growth rate of 5.6%, is due to several factors. These include the increasing prevalence of minimally invasive procedures, an aging population, improved access to advanced treatment methods, a shift towards patient-focused care, and a higher incidence of comorbid conditions. Key trends anticipated during this forecast period encompass the development of specific therapies, the incorporation of digital health technologies, advancements in surgical procedures, the use of 3D imaging for diagnosis and the introduction of innovative patient-centered care approaches.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21112

What Are the Emerging Segments Within the Benign Prostatic Hyperplasia Treatment Market?
The benign prostatic hyperplasia treatment market covered in this report is segmented -

1) By Treatment: Minimal Invasive Surgery, Invasive Surgery
2) By Therapeutic Class: Alpha Blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Other Therapeutic classes
3) By End User: Home Healthcare, Hospitals And Clinics, Research And Manufacturing

Subsegments:
1) By Minimal Invasive Surgery: Transurethral Resection of the Prostate (TURP), Laser Surgery, Prostatic Urethral Lift, Transurethral Incision of the Prostate (TUIP), Microwave Therapy
2) By Invasive Surgery: Open Prostatectomy, Robotic Prostatectomy

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21112&type=smp

What Long-Term Drivers Are Shaping Benign Prostatic Hyperplasia Treatment Market Trends?
As minimally invasive procedures garner popularity, the benign prostatic hyperplasia treatment market is on track for substantial growth. This progression in surgical approaches can be traced back to their unique benefits as minimally invasive surgeries which barely require any incision, thus dramatically reducing the risk of complications and the period of recovery. Not to mention, such procedures also alleviate pain and optimize aesthetic outcomes. In the specific context of benign prostatic hyperplasia treatment, minimally invasive surgeries have proven to be a boon; they pave the way for quicker recovery, fewer complications, and symptom relief which cumulatively contribute to an elevated surgical result. To exemplify, the American Society of Plastic Surgeons (ASPS) recorded a whopping 23,672,269 cosmetic minimally invasive procedures undertaken around the world in 2022. Such treatments ranged from neuromodulator injections and lip augmentation to non-invasive skin tightening. Hence, the increasing adoption of minimally invasive surgeries clearly spells a bullish trend for the benign prostatic hyperplasia treatment market.

Who Are the Top Competitors in Key Benign Prostatic Hyperplasia Treatment Market Segments?
Major companies operating in the benign prostatic hyperplasia treatment market are Pfizer Inc., Merck And Co Inc, AbbVie Inc., Bayer AG, Sanofi S.A., GlaxoSmithKline Public Limited Company, Medtronic Public Limited Company, Mezzion Pharma Co Ltd, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Boston Scientific Corporation, Astellas Pharma Inc., Olympus Corporation, Coloplast Group, Teleflex Incorporated, Cook Medical Incorporated, AngioDynamics, Inc., HistoSonics Inc, Urovant Sciences Ltd, UroGen Pharma Ltd., Urologix Inc, Zenflow Inc, Butterfly Medical Ltd.

What Trends Are Expected to Dominate the Benign Prostatic Hyperplasia Treatment Market in the Next 5 Years?
Key players in the benign prostatic hyperplasia treatment market are focusing their efforts on creating advanced solutions such as minimally invasive operations to improve patient results and reduce recovery duration. These approaches, which require tiny or no cuts, limit trauma, discomfort, and complications while speeding up the recovery process in comparison to conventional surgical techniques. For example, Teleflex Incorporated, an American medical device corporation, introduced the UroLift System for the management of benign prostatic hyperplasia in December 2022. By employing minuscule permanent implants to shift the extended prostate tissue, this system offers significant relief without requiring tissue removal, cutting, or heating. This outpatient procedure ensures swift recovery, retains sexual function, and provides superior symptom alleviation in comparison to traditional BPH medicines, with side effects typically subsiding within a span of two to four weeks.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/benign-prostatic-hyperplasia-treatment-global-market-report

Which Regions Are Becoming Hubs for Benign Prostatic Hyperplasia Treatment Market Innovation?
North America was the largest region in the benign prostatic hyperplasia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the benign prostatic hyperplasia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Benign Prostatic Hyperplasia Treatment Market?
2. What is the CAGR expected in the Benign Prostatic Hyperplasia Treatment Market?
3. What Are the Key Innovations Transforming the Benign Prostatic Hyperplasia Treatment Industry?
4. Which Region Is Leading the Benign Prostatic Hyperplasia Treatment Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.